ACADIA Pharmaceuticals Inc. (ACAD) Profit Margins
Over the twelve months to 2026-06-30, ACADIA Pharmaceuticals Inc. (ACAD) had gross margin 91.1%, operating margin 7.6%, net margin 33.4%, free cash flow margin 12.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACADACADIA Pharmaceuticals Inc.Follow ACAD — free
—
Price chart with a free account
- Market cap
- 3.4B
- P/E TTM
- 8.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% | 91.1% | |
| Operating margin | -1105.6% | -425.6% | -3344.7% | -77691.7% | -269855.7% | -1574.1% | -234.1% | -110.6% | -72.7% | -64.9% | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% | 7.6% | |
| Net margin | -1101.4% | -424.9% | -3314.2% | -77062.5% | -269578.7% | -1565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% | 33.4% | |
| FCF margin | — | — | -2828.6% | -55511.7% | -203173.8% | -1211.2% | -175.0% | -75.8% | -44.9% | -32.5% | -26.2% | -22.0% | 2.3% | 16.4% | 9.8% | 12.8% |
USD billions · SEC XBRL
ACADIA Pharmaceuticals Inc. — questions
- What is ACADIA Pharmaceuticals Inc.'s gross margin?
- 91.1% over the twelve months to 2026-06-30.
- What is ACADIA Pharmaceuticals Inc.'s operating margin?
- 7.6% over the twelve months to 2026-06-30.
- What is ACADIA Pharmaceuticals Inc.'s net profit margin?
- 33.4% over the twelve months to 2026-06-30.
Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.